Long-term mizoribine intermittent pulse therapy, but not azathioprine therapy, attenuated histologic progression in a patient with severe lupus nephritis [2]

Clinical Nephrology

Volumn 68, Issue 3, 2007, Pages 198-200

  Tanaka, H ^a   Tsugawa, K ^a   Oki, E ^a   Suzuki, K ^a   Waga, S ^b   Ito, E ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Namioka   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROGEN; PREDNISOLONE; UREA;

ACUTE KIDNEY FAILURE; ADOLESCENT; ANTIBODY BLOOD LEVEL; CASE REPORT; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY BIOPSY; LETTER; LONG TERM CARE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; PROLIFERATIVE GLOMERULONEPHRITIS; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; UREA NITROGEN BLOOD LEVEL;

EID: 34548487309     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68198     Document Type: Letter

References (10)

1. Austin HA, Muenz LR, Joyce KM, Antonnovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984; 25: 689-695.
2. Itoh H, Komatsuda A, Wakui H, Miura AB, Tashima Y. Mammalian HSP60 is a major target for an immunosuppressant mizoribine. J Biochem. 1999; 274: 35147-35151.
3. Kawasaki Y, Hosoya M, Suzuki J, Onishi N, Takahashi A, Isome M, Nozawa R, Suzuki H. Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methyprednisolone pulse therapy. Am J Nephrol. 2004; 24: 576-581.
4. Lai KN, Tang SCW, Mok CC. Treatment for lupus nephritis: a revisit. Nephrology. 2005; 10: 180-188.
5. Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus. 2000; 9: 445-450.
6. Nakahata T, Tsugawa K, Waga S, Tanaka H. Acute renal failure with encephalopathy following Salmonella enteridis infection. Pediatr Nephrol. 2006; 21: 1209-1210.
7. Sato N, Shiraiwa K, Kai K, Watanabe A, Ogawa S, Kobayashi Y, Yamagihi-Imai H, Utsunomiya Y, Mitarai T. Mizoribine ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. Nephron. 2001; 89: 177-185.
8. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin Nephrol. 2003; 60: 390-394.
9. Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, Ito E. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol. 2005; 63: 417-422.
10. Tanaka H, Tsugawa K, Suzuki K, Nakahata T, Ito E. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis. Pediatr Nephrol. 2006; 21: 962-966.